Can a Chemo-Immunotherapy combo outsmart resistant colorectal cancer?
NCT ID NCT05504252
First seen Jan 07, 2026 · Last updated Jun 22, 2026 · Updated 20 times
Summary
This phase 2 trial is testing whether adding the immunotherapy drug nivolumab (Opdivo) to standard chemotherapy (oxaliplatin, 5-fluorouracil, folinic acid) can help control or shrink a hard-to-treat type of metastatic colorectal cancer (pMMR/MSS). The study includes 80 adults whose cancer has spread and who have not had prior chemotherapy. The goal is to see if this combination improves how long the cancer stays under control and overall survival.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for COLORECTAL ADENOCARCINOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Akershus University Hospital
Lørenskog, Akershus, 1478, Norway
-
Oslo University Hospital
Oslo, Akershus, 0424, Norway
-
St Olavs Hospital
Trondheim, Trøndelag, 7006, Norway
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
nivolumab (Opdivo) and oxaliplatin (with 5-fluorouracil and folinic acid)
What this could lead to
If successful, this combination could offer a new treatment option for people with a hard-to-treat form of colorectal cancer, potentially improving disease control and survival.
What could go wrong
This is a phase 2 trial with only 80 participants, so results are preliminary. The cancer type is known to be resistant to immunotherapy, and the added benefit of nivolumab is uncertain. Side effects from both drugs are possible.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.